In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Victoria Sergeevna ShchekinaFederal State Budgetary Scientific Institution "Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies", Moscow 125315, Russia.ORCID 0009-0006-6204-166X Nikita Aleksandrovich BatashkovFederal State Budgetary Scientific Institution "Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies", Moscow 125315, Russia.ORCID 0009-0004-2562-2401 Anna Arkadievna MazninaFederal State Budgetary Scientific Institution "Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies", Moscow 125315, Russia.ORCID 0000-0002-5780-1330 Julia Aleksandrovna KrupinovaFederal State Budgetary Scientific Institution "Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies", Moscow 125315, Russia.ORCID 0000-0001-7963-5022 Viktor Pavlovich BogdanovFederal State Budgetary Scientific Institution "Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies", Moscow 125315, Russia.ORCID 0000-0001-6377-9056 Anna Vasilievna KorobeinikovaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 119121, Russia.ORCID 0009-0003-0556-9343 Dmitry Igorevich TychininFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 119121, Russia.ORCID 0009-0000-2032-537X Olga Valentinovna GlushkovaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 119121, Russia.ORCID 0000-0002-0257-6439 Ekaterina Sergeevna PetriaikinaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 119121, Russia.ORCID 0000-0001-6680-6515 Dmitry Vladimirovich SvetlichnyyFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 119121, Russia.ORCID 0000-0002-3776-9871 Vladimir Sergeevich YudinFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 119121, Russia.ORCID 0000-0002-9199-6258 Anton Arturovich KeskinovFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 119121, Russia.ORCID 0000-0001-7378-983X Sergey Mikhailovich YudinFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 119121, Russia.ORCID 0000-0002-7942-8004 Veronika Igorevna SkvortsovaThe Federal Medical Biological Agency (FMBA of Russia), Moscow 123182, Russia.ORCID 0000-0003-2815-280X Dmitry Vyacheslavovich TabakovFederal State Budgetary Scientific Institution "Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies", Moscow 125315, Russia.ORCID 0000-0002-1509-2206 Andrei Andreevich DeviatkinFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 119121, Russia.ORCID 0000-0003-0789-4601 Pavel Yu VolchkovFederal State Budgetary Scientific Institution "Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies", Moscow 125315, Russia.ORCID 0000-0001-9794-6297 Funding
ANO "Moscow Center for Innovative Healthcare technologies" № 1309-4/25Ministry of Science and Higher Education of the Russian Federation FGFG-2025-0015
6 · The paper itselfAbstract
Polygenic autoimmune diseases (ADs) have several common features that are caused by a complex interplay of genetic and environmental factors. Common pathophysiological mechanisms include dysregulation of the immune system, chronic inflammation, and epigenetic changes influenced by external factors. For the prediction of the genetic predisposition of AD manifestation, polygenic risk scale (PRS), or polygenic scores (PGSs), are used. Use of PRSs faces several challenges such as applicability on a specific population, performance comparison, and estimation of biological relevance based on SNP number. We compared PRS with different numbers of SNPs and tried to find the common genetic core of ADs. Our analysis revealed a list of the most common altered genes, which we annotated and interpreted. Clustering of PRS based on used genes showed that clusters of ADs remained consistent across all chosen PRS sizes. We concluded that PRS size does not have an impact on biological relevance.
Indexed as
Autoimmune DiseasesGenetic Predisposition to DiseaseMultifactorial InheritanceGenetic Risk ScoreGenome-Wide Association StudyHumansPolymorphism, Single Nucleotideautoimmune diseasepolygenic risk scorePRSSNP
Identifiers
PMID41516417
PMCPMC12786532
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390